Marcon Magda, Frauenfelder Thomas, Becker Anton S, Dedes Konstantin J, Boss Andreas
Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland.
Department of Gynecology, University Hospital Zurich, Switzerland.
Eur J Radiol. 2017 Apr;89:226-233. doi: 10.1016/j.ejrad.2017.02.012. Epub 2017 Feb 16.
To evaluate the outcome of repeated short-term follow-up with ultrasound in no high-risk young patients with a BI-RADS3 lesion at first examination.
In this IRB-approved study 492 women, aged 18-34 years (mean±standard deviation, 28±4.5years) with first breast ultrasound examination in 2012-2014 were retrospectively evaluated. Inclusion criteria were: at least one BI-RADS3 lesion and (a) biopsy/surgical excision or (b) follow-up of at least 18 months (including a 6-month follow-up). BI-RADS category assigned during follow-up and pathologic findings in cases undergoing biopsy/surgical excision were collected. At the 6- and 18-month follow-up the recommended biopsy rates (RBR) and the corresponding positive predictive value (PPV) were calculated.
In 97 patients, 151 BI-RADS3 lesions were identified. Biopsy/surgical excision was initially performed in 25/151 (16.5%) lesions. After 6-month, category was downgraded to BI-RADS1/2 in 23/126 (15.3%) and upgraded to BI-RADS4 in 9/126 lesions (7.1%). Pathological diagnosis of these lesions was fibroadenoma in 5 and benign phyllodes tumor in 4 cases (RBR 7%, PPV 44.4%). After 18-month one lesion was classified BI-RADS4 and pathological diagnosis was fibroadenoma (RBR 1.1%, PPV 0%).
Our preliminary data show that follow-up imaging performed after 18 months from a first BI-RADS3 diagnosis does not affect clinical treatment and 6-month follow-up may be sufficient to assess the stability of probably benign lesions.
评估首次检查为BI-RADS 3类病变的无高危因素年轻患者重复进行短期超声随访的结果。
在这项经机构审查委员会批准的研究中,对2012年至2014年首次进行乳腺超声检查的492名年龄在18至34岁(平均±标准差,28±4.5岁)的女性进行了回顾性评估。纳入标准为:至少有一个BI-RADS 3类病变,且(a)进行活检/手术切除,或(b)随访至少18个月(包括6个月随访)。收集随访期间分配的BI-RADS分类以及活检/手术切除病例的病理结果。在6个月和18个月随访时,计算推荐活检率(RBR)和相应的阳性预测值(PPV)。
在97名患者中,共识别出151个BI-RADS 3类病变。最初对25/151(16.5%)个病变进行了活检/手术切除。6个月后,126个病变中有23个(15.3%)类别降级为BI-RADS 1/2,9个(7.1%)病变升级为BI-RADS 4类。这些病变的病理诊断为5例纤维腺瘤和4例良性叶状肿瘤(RBR 7%,PPV 44.4%)。18个月后,1个病变分类为BI-RADS 4类,病理诊断为纤维腺瘤(RBR 1.1%,PPV 0%)。
我们的初步数据表明,首次BI-RADS 3类诊断后18个月进行的随访成像不影响临床治疗,6个月随访可能足以评估可能为良性病变的稳定性。